Abstract
In this work, we stratify 428 bulk RNA-seq spinal cord transcriptomes from 206 ALS patients to assess concordance with cortical phenotype. We find the postmortem spinal cord generally recaptures the molecular phenotypes observed in the postmortem cortex and observe weaker differences in patient survival after correction for repeat measures. We compare intra-patient subtype assigned in the cortex and spinal cord, finding modest agreement between the cortex and lumbar region specifically, ranging from 46.2 – 66.7%. We leverage differential expression analysis to identify seven marker genes for the oxidative stress (ALS-Ox) subtype that show consistent upregulation in both the cortex and spinal cord and utilize three to construct classifiers that achieve notable predictive power for the ALS-Ox subtype in three different holdout cohorts, with AUCs ranging from 0.81 – 0.89. Our study shows the ALS-Ox subtype is conserved in the spinal cord of the same patients, offering a postmortem foundation for clinical stratification.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Flinn Foundation (22-06449). J.E. is supported by the National Science Foundation, Graduate Research Fellowship (026257-001). J.F. received financial support from the French government in the framework of the France 2030 program IdEx Universite de Bordeaux
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Original Study Approval: The NYGC ALS Consortium samples presented in this work were acquired through various IRB protocols from member sites and the Target ALS postmortem tissue core and transferred to the NYGC in accordance with all applicable foreign, domestic, federal, state, and local laws and regulations for processing, sequencing, and analyses. Postmortem brain tissues from cognitively normal individuals were obtained from the Mayo Clinical Florida Brain Bank. Diagnosis was independently ascertained by trained neurologists and neuropathologists upon neurological and pathological examinations, respectively. Written informed consent was given by all participants or authorized family members, and all protocols were approved by the IRB and ethics committee of the Mayo Clinic.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The raw RNA-seq data files used in this study are available in the NCBI Run Selector database under accession code PRJNA644618. The RSEM processed gene count matrix utilized in this study are available in the Gene Expression Omnibus database under accession code GSE153960. Transposable elements and processed RNA-seq count files are available as supplemental datasets or made publicly available at: https://figshare.com/authors/Jarrett_Eshima/13813720.
